文献速递免疫规划卫生政策与健康促进

重新思考老年人肺炎球菌结合疫苗的需接种人数:当前与未来的意义

Rethinking number-needed-to-vaccinate for pneumococcal conjugate vaccines in older adults: Current and future implications.
PubMed 文献 · Vaccine · 2017-08-31

该研究构建20万65岁及以上美国成人假设固定队列,比较两种计算13价肺炎球菌结合疫苗(PCV13)预防一例社区获得性肺炎(CAP)的需接种人数(NNV)方法:按CDC原法用1年绝对率差,以及用5年绝对风险降低。结果显示5年累积效应下NNV约为原估计的三分之一,忽略累积效应会严重低估成人PCV13的公共卫生影响。

要点

  • 按CDC 2014年原法(1年率差),PCV13预防一例住院和门诊CAP的NNV分别为1620和1110。
  • 计入5年累积效应后,预防一例住院和门诊CAP的NNV分别为576和394,约为原估计的三分之一。
  • 一剂PCV13在5年内预防任何CAP(住院或门诊)的NNV为234。

核心结论

  • 计入PCV13接种随时间累积的预防效应至关重要,否则即使使用保守的疾病负担参数,也会严重低估成人PCV13使用的公共卫生影响。

研究设计与样本

  • 构建20万65岁及以上美国成人假设固定队列,均分为PCV13接种组和未接种组,采用CDC 2014年保守假设进行建模比较。

主要发现

  • 按CDC 2014年原法计算,PCV13预防一例住院CAP和门诊CAP的NNV分别为1620和1110。
  • 计入5年累积效应后,PCV13预防一例住院CAP和门诊CAP的NNV分别为576和394,约为忽略累积效应初始估计的三分之一。
  • 一剂PCV13在5年内预防任何CAP(住院或门诊)的NNV为234。

关键数值与推荐

  • 住院CAP年发病率1375/10万,门诊CAP年发病率2010/10万。
  • 2014年成人PCV13型CAP占比10%,PCV13对疫苗型CAP效力45%。
  • 两组年死亡率均假设为5%,成人PCV13型CAP占比因儿童群体效应逐年下降,PCV13效力5年内不衰减。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Number-needed-to-vaccinate (NNV) is increasingly used to inform decisions about vaccine use, but it is not calculated uniformly across studies. This study compared two methodologies for calculating NNV with 13-valent pneumococcal conjugate vaccine (PCV13) to prevent one case of community-acquired pneumonia (CAP) among US adults aged ≥65years: (i) using one-year absolute rate differences as was originally performed by the Centers for Disease Control and Prevention (CDC) and (ii) using absolute risk reduction over 5years. METHODS: We constructed a hypothetical fixed cohort of 200,000 adults aged ≥65years equally separated into PCV13-vaccinated and PCV13-unvaccinated groups. We incorporated the same conservative assumptions used by CDC in 2014 regarding annual incidence of hospitalized (1375 per 100,000) and outpatient (2010 per 100,000) CAP, the initial (2014) proportion of adult PCV13-type CAP (10%), and PCV13 efficacy against vaccine-type CAP (45%). To model PCV13 impact over time, we assumed annual mortality was 5% for both groups, the percentage of adult PCV13-type CAP declined annually due to pediatric herd effects, and PCV13 efficacy did not wane over 5years. RESULTS: Among adults aged ≥65years, NNV with PCV13 to prevent one hospitalized and one outpatient case of CAP as originally calculated by CDC in 2014 were 1620 and 1110, respectively. Accounting for 5-year cumulative effects, NNV with PCV13 to prevent one hospitalized and one outpatient case of CAP over 5years were 576 and 394, respectively. These revised NNV estimates are roughly one third of initial estimates in which cumulative effects were ignored. NNV to prevent any CAP (inpatient or outpatient) over 5years with one PCV13 dose was 234. CONCLUSION: Accounting for cumulative preventive effects of PCV13 vaccination over time is critical. Failing to do so, even when using conservative disease burden parameters, can grossly underestimate the public health impact of adult PCV13 use.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. McLaughlin JM, Swerdlow DL, Isturiz RE, et al. Rethinking number-needed-to-vaccinate for pneumococcal conjugate vaccines in older adults: Current and future implications. Vaccine. 2017. PMID: 28863866. doi:10.1016/j.vaccine.2017.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。